Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives $4.50 Consensus PT from Analysts

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the six research firms that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold re…

Read Full Article →